TY - JOUR
T1 - Effect of metformin and lifestyle interventions on mortality in the diabetes prevention program and diabetes prevention program outcomes study
AU - Diabetes Prevention Program Research Group
AU - Lee, Christine G.
AU - Heckman-Stoddard, Brandy
AU - Dabelea, Dana
AU - Gadde, Kishore M.
AU - Ehrmann, David
AU - Ford, Leslie
AU - Prorok, Philip
AU - Boyko, Edward J.
AU - Pi-Sunyer, Xavier
AU - Wallia, Amisha
AU - Knowler, William C.
AU - Crandall, Jill P.
AU - Temprosa, Marinella
N1 - Publisher Copyright:
© 2021 by the American Diabetes Association.
PY - 2021/12
Y1 - 2021/12
N2 - OBJECTIVE To determine whether metformin or lifestyle modification can lower rates of all-cause and cause-specific mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. RESEARCH DESIGN AND METHODS From 1996 to 1999, 3,234 adults at high risk for type 2 diabetes were randomized to an intensive lifestyle intervention, masked metformin, or placebo. Placebo and lifestyle interventions stopped in 2001, and a modified lifestyle program was offered to everyone, but unmasked study metformin continued in those origi-nally randomized. Causes of deaths through 31 December 2018 were adjudicated by blinded reviews. All-cause and cause-specific mortality hazard ratios (HRs) were estimated from Cox proportional hazards regression models and Fine-Gray models, respectively. RESULTS Over a median of 21 years (interquartile range 20–21), 453 participants died. Cancer was the leading cause of death (n = 170), followed by cardiovascular disease (n = 131). Compared with placebo, metformin did not influence mortality from all causes (HR 0.99 [95% CI 0.79, 1.25]), cancer (HR 1.04 [95% CI 0.72, 1.52]), or cardiovascular disease (HR 1.08 [95% CI 0.70, 1.66]). Similarly, lifestyle modification did not impact all-cause (HR 1.02 [95% CI 0.81, 1.28]), cancer (HR 1.07 [95% CI 0.74, 1.55]), or cardiovascular disease (HR 1.18 [95% CI 0.77, 1.81]) mortality. Analyses adjusted for diabetes status and duration, BMI, cumulative glycemic exposure, and cardiovascular risks yielded results similar to those for all-cause mortality. CONCLUSIONS Cancer was the leading cause of mortality among adults at high risk for type 2 diabetes. Although metformin and lifestyle modification prevented diabetes, nei-ther strategy reduced all-cause, cancer, or cardiovascular mortality rates.
AB - OBJECTIVE To determine whether metformin or lifestyle modification can lower rates of all-cause and cause-specific mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. RESEARCH DESIGN AND METHODS From 1996 to 1999, 3,234 adults at high risk for type 2 diabetes were randomized to an intensive lifestyle intervention, masked metformin, or placebo. Placebo and lifestyle interventions stopped in 2001, and a modified lifestyle program was offered to everyone, but unmasked study metformin continued in those origi-nally randomized. Causes of deaths through 31 December 2018 were adjudicated by blinded reviews. All-cause and cause-specific mortality hazard ratios (HRs) were estimated from Cox proportional hazards regression models and Fine-Gray models, respectively. RESULTS Over a median of 21 years (interquartile range 20–21), 453 participants died. Cancer was the leading cause of death (n = 170), followed by cardiovascular disease (n = 131). Compared with placebo, metformin did not influence mortality from all causes (HR 0.99 [95% CI 0.79, 1.25]), cancer (HR 1.04 [95% CI 0.72, 1.52]), or cardiovascular disease (HR 1.08 [95% CI 0.70, 1.66]). Similarly, lifestyle modification did not impact all-cause (HR 1.02 [95% CI 0.81, 1.28]), cancer (HR 1.07 [95% CI 0.74, 1.55]), or cardiovascular disease (HR 1.18 [95% CI 0.77, 1.81]) mortality. Analyses adjusted for diabetes status and duration, BMI, cumulative glycemic exposure, and cardiovascular risks yielded results similar to those for all-cause mortality. CONCLUSIONS Cancer was the leading cause of mortality among adults at high risk for type 2 diabetes. Although metformin and lifestyle modification prevented diabetes, nei-ther strategy reduced all-cause, cancer, or cardiovascular mortality rates.
UR - http://www.scopus.com/inward/record.url?scp=85120968236&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120968236&partnerID=8YFLogxK
U2 - 10.2337/dc21-1046
DO - 10.2337/dc21-1046
M3 - Article
C2 - 34697033
AN - SCOPUS:85120968236
SN - 0149-5992
VL - 44
SP - 2775
EP - 2782
JO - Diabetes care
JF - Diabetes care
IS - 12
ER -